Seattle Genetics at all-time high on strength of breast cancer readout

Seattle Genetics added more than $2 billion in market cap Monday after reporting pivotal survival data for breast cancer therapy tucatinib, a TKI targeting HER2 which is designed to have a favorable toxicity profile compared with others in its class. The gains are more than three times the amount Seattle Genetics paid to acquire Cascadian Therapeutics Inc. last year, giving it a pipeline that includes the therapy.

Results from the registrational Phase II HER2CLIMB

Read the full 739 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE